Results 221 to 230 of about 134,407 (301)

Psychiatric Disorders and Apathy in Mixed Movement Disorders Linked to ADCY5 (MxMD‐ADCY5)

Movement Disorders, EarlyView.
Abstract Background Mixed movement disorders linked to ADCY5 (MxMD‐ADCY5) represent a rare hyperkinetic movement disorder resulting from pathogenic variants in ADCY5. Psychiatric symptoms are suspected to be part of the phenotype. Objective The study aim was to assess psychiatric comorbidities in patients with MxMD‐ADCY5.
Aurélie Méneret, Clément Tarrano, Asya Ekmen, Diane Doummar, Victoria Gonzalez, Christine Tranchant, Mathieu Anheim, Philippe Damier, Eoin Mulroy, Kailash P. Bhatia, Laura Cif, Carlo Fusco, Miryam Carecchio, Norbert Brüggemann, Alexander Münchau, Florence Riant, Manon Gomes, Vanessa Brochard, Agathe Roubertie, Oriane Trouillard, Caroline Dubacq, Yulia Worbe, Mohamed Doulazmi, Emmanuel Roze   +23 more
wiley   +1 more source

Polygenic risk for schizophrenia predicting test-measured and self-reported cognitive performance in individuals without psychosis. [PDF]

BMC Psychiatry
Rosenqvist E, Lyytikäinen LP, Sormunen E, Kähönen M, Raitakari O, Hietala J, Pahkala K, Lehtimäki T, Keltikangas-Järvinen L, Rovio S, Saarinen A.   +10 more
europepmc   +1 more source

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

Movement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani, František Váša, Latha Velayudhan, Sagnik Bhattacharyya   +3 more
wiley   +1 more source

The effect of age on the clinical presentation and treatment of women with psychosis: secondary analysis of the IMPaCT Randomised Clinical Trial. [PDF]

BJPsych Open
Nettis MA, Ismail K, Murray RM, Dima A, Greenwood K, Atakan Z, Smith S, Gaughran F.   +7 more
europepmc   +1 more source

Perspective: Depression in Persons with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Depression is a prevalent and disabling syndrome characterized by sustained sadness and/or anhedonia, as well as cognitive and physical symptoms. In Parkinson's disease (PD), depression is both common and clinically challenging due to overlapping symptoms and complex etiologic interactions. Major depressive disorder occurs in approximately 17%
Albert F.G. Leentjens, Gregory M. Pontone   +1 more
wiley   +1 more source

Prevalence of clinically significant radiological abnormalities in people with first episode psychosis. [PDF]

World Psychiatry
Reilly TJ, Butler M, Abdelsamie A, Awatli I, Barai S, Baxter L, Boardman-Pretty T, Phelps R, Waqar A, Jewell A, Blackman G, Oliver D, Venkataraman AV, Kempton MJ, McGuire P.   +14 more
europepmc   +1 more source

Temporal Interference Stimulation Modulates Resting State Functional Connectivity of Motor Circuit in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Transcranial temporal interference stimulation (TIs) targeting the subthalamic nucleus (STN) is a novel noninvasive neuromodulation approach with potential to improve motor symptoms in Parkinson's disease (PD). However, its underlying neuroimaging mechanisms remain unclear.
Yongxin Xu, Chenhao Yang, Yichao Du, Xiaonan Shen, Tingting Li, Yufeng Zhang, Zijun Lu, Jie Zhuang, Nan Chen, Yulian Zhu, Chencheng Zhang, Jiaojiao Lü, Lingyan Huang, Lu Li, Jianqiang Lü, Zhenyu Qian, Zhen Wang, Jian Zhang, Junhong Zhou, Yu Liu   +19 more
wiley   +1 more source

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. [PDF]

BMJ Ment Health
Launders N, Richards-Belle A, Hardoon S, Man K, Wong ICK, Osborn DPJ, Hayes JF.   +6 more
europepmc   +1 more source

Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Keita Kakuda, Yasuyoshi Kimura, Lindun Ge, Kensuke Ikenaka, Kanako Asai, Shunpei Murakami, Kotaro Ogawa, Hideki Mochizuki   +7 more
wiley   +1 more source